This weekend in the oncology conference calendar saw the ESMO Breast meeting take place.
The event was originally planned as a live event in Berlin – sadly with the pandemic it ended up as a virtual meeting on Central European time, yet you can still imagine the Berlin bear welcoming everyone regardless of format!
This is a good time to take off we we left off last week with our SERD landscape review since there was some new clinical data presented in this niche, as well as segue to the ASCO meeting on Friday where other companies will also be showcasing their early data.
Aside from SERDs, there were plenty of other highlights and commentary to consider in advanced breast cancer.
Here we explore some of the findings and offer some context for at least one commercial showdown…
To learn more from our oncology analysis and get a heads up on insights and commentary emerging from the ESMO Breast and ASCO meetings, subscribers can log-in or you can click to gain access to BSB Premium Content.
Imagine arriving at ESMO19 at the crack of dawn for a press briefing and you’re not presenting until after 4.30pm!
To whom is it a benefit is a fundamental principle in modern day medicine given the often vast array of options that oncologists may have at their disposal.
Conversely, we also need to know nec refert – for whom it doesn’t matter or doesn’t benefit – since we don’t want to over-treat people either.
Between those two extremes might be a couple of sweetspots i.e. one subset who may need a boost from chemotherapy and another in whom chemo plus IO therapy might be a better option.
For sure, we are not advocating that all people with early stage triple negative breast cancer (TNBC) should receive the same thing and certainly not everyone will need checkpoint therapy, no matter what the intent-to-treat (ITT) curves or response rates might try to imply.
There’s a lot of factors to think about and consider so here we look at the KEYNOTE–522 data in neoadjuvant and adjuvant TNBC and unearthed with some solid evidence that might help us understand and think about what needs to be done.
Following on from our in-depth ESMO19 Preview on TNBC and what to watch out for, we also now have a thought leader interview to share plus several other commentators chipping in…
To learn more from our latest coverage on early stage triple negative breast cancer and get a heads up on our latest thought leader interview, subscribers can log-in or you can click to gain access to BSB Premium Content.
One of the expected highlights of the forthcoming European Society for Medical Oncology (Twitter #ESMO19) will be data for breast cancer immunotherapy.
In the first of our pre-ESMO19 previews we are taking a closer look at three breast cancer immunotherapy presentations that we think are noteworthy.
As a reminder, the abstracts are not yet available, so we’re not writing about data that’s not yet been presented, but instead are looking at why the presentations may be of scientific/medical interest, and what the questions we hope they will answer. In cancer biology as we heard from Professor Gerard Evan in a recent expert interview, it’s not about “what” happened, but “why”?
We have “boots on the ground” in Barcelona from Sept 27th to October 1st providing daily posts for BSB subscribers with our unique blend of data, analysis and commentary.
Do download the ESMO19 app if you want to check out what already looks like it will be a busy, informative and interesting congress in Barcelona. Hopefully the rain that struck the recent World Lung meeting in Barcelona will have gone away, leaving us with a sunny and dry spell one normally associates with Spain!
To learn more from our latest oncology conference insights and get a heads up on our latest ESMO Preview, subscribers can log-in or you can click to gain access to BSB Premium Content.
The 2019 annual meeting of the American Society of Clinical Oncology (Twitter #ASCO19) is now in full swing, and we’re kicking off our on-site meeting coverage with a review of the some of the highlights of Friday here in Chicago.
In today’s Daily Highlights we offer seven areas of interest and offer commentary on the insights gleaned from the data that is rolling out so far…
To learn more from our latest conference coverage and oncology insights, subscribers can log-in or you can click to gain access to BSB Premium Content.
AstraZeneca miss on OS in the phase 3 MYSTIC trial – what next?
Getting there… in 1L NSCLC
At one point we were posting almost quarterly updates on the runners and riders in the 1L NSCLC niche and what a roller coaster it has turned out to be!
There have been some successes, failures, and even mixed results so far, suggesting that there’s no room for complacency here.
Previously, AstraZeneca were the first to readout out on PFS in the MYSTIC trial and missed, meaning they had to go to the back of the queue and patiently await the OS data. Since then, we’ve seen several phase 3 trials from Merck, Genentech/Roche and BMS all readout without any real rhyme, reason or consistency between them.
Now AstraZeneca are back in the spotlight with a not altogether unexpected miss on median OS.
It’s easy for people to kick a dog when it’s down rather than take a moment to reflect on the deeper meaning – what does the result mean both for the company and other key players in this highly competitive landscape? What can we learn from this experience and other recent results?
To answer that, we put some insights and analysis together in our latest update on the space…
To learn more about our latest insights, subscribers can log-in or you can purchase access to BSB Premium Content…
It is always a pleasure to talk with experts who have a clear vision of not just what the current treatment landscape looks like, but where the field is going.
Dr Stephen Liu at ASCO18
Dr Stephen Liu is a medical oncologist and assistant professor at Georgetown University Medical Center in Washington DC, where he specializes in thoracic oncology. He’s also actively involved in clinical trials and developmental therapeutics.
We last interviewed him at ASCO 2016 – you can also hear him on Episode 13 of the Novel Targets Podcast – where he shared his thoughts on some of the early lung cancer immunotherapy combination trials underway.
As regular readers know, we like to follow stories over time and also catch up with thoughtful, intelligent people we’ve talked to in the past whose opinions we value.
Dr Liu kindly shared his highlights of ASCO 2018 in lung cancer, and in a wide ranging discussion, also offered some thoughts on what the future may hold and where we may be going next.
There was a lot to learn from Chicago this year, with plenty of nuances and subtleties to consider. If you read only one post on lung cancer from ASCO18, this interview tells you all you need to know!
To learn more and get a heads up on our latest expert interview and oncology insights, subscribers can log-in or you can click to gain access to BSB Premium Content.
At AACR last week we had the long awaited initial readouts for three key phase 3 studies in lung cancer, namely CheckMate–227, IMpower150, and KEYNOTE–189 in the same session on the same day.
This had me thinking about how it might end up being, “a killer and a chiller and a thriller when I get the (PD–1) gorilla in Manila,” with sincere apologies to Muhammed Ali and Dr Jean-Charles Soria for (mis)appropriating their past themes 😉
Chicago River Bridge at #AACR18
For those attending the event, you might well be forgiven for thinking from the first two adjectives that I’m referring to the weather, as it was certainly cold enough (!), or even the results this week from AstraZeneca’s unfortunately named ARCTIC study exploring the IO-IO combo of durvalumab plus tremelimumab in the third line setting with a miss in both PFS and OS endpoints.
In reality, we should be warmed and heartened to see three positive immunotheraopy trials appear at once and presented in the same session at the same meeting. It isn’t always the case as regular attendees at ASCO well know.
When all is said and done, what do thought leaders specialising in lung cancer really think about the data that was presented in Chicago, and what were the convergence and discord on the various key issues under consideration? There is, after all, a lot of subtlety and nuance to consider in 1L NSCLC.
To find out more, we interviewed not one, but four, lung cancer specialists in Chicago for their personal perspectives. What they had to say as a group was both candid and absolutely fascinating, so it made sense to curate their insights around various key topics together into one detailed post for easy reading…
To learn more and get a heads up on our latest thought leader interviews and oncology insights, subscribers can log-in or you can click to gain access to BSB Premium Content.
The first cancer conference of 2018 is now upon us and after enjoying last year’s event in San Francisco, I wanted to take some time to explore some key abstracts of interest at the ASCO GI meeting, which begins tomorrow.
This conference covers various updates on new developments in oesophageal, gastric, colon, pancreatic and colorectal cancers.
Are there any trials or new developments to get excited about at this year’s GI18 meeting?
To find out and get a heads up on our latest conference coverage, subscribers can log-in or you can click to gain access to BSB Premium Content.
After writing about the 1L NSCLC landscape every quarter last year, I was thinking the other day that we were due another update and discussion on this riveting topic again soon and added it to the editorial calendar of topics to write about on BSB.
It was therefore no surprise to hear Merck’s announcement this morning that their phase 3 trial KEYNOTE-189 exploring pembrolizumab plus chemotherapy hit its co-primary endpoints and is now the second study to do so after Genentech/Roche’s announcement for atezolizumab plus chemo plus the VEGF inhibitor, bevacizumab was a success.
Are we at a crossroad for lung cancer? With many more readouts yet to come competition in this space is certainly heating up dramatically!
Meanwhile, there are a few important implications to consider here, so we sat down and penned an update based on the emerging data and highlight some key insights to consider…
To learn more and get a heads up on our thought leader interview, subscribers can log-in or you can click to gain access to BSB Premium Content.
It really doesn’t feel like a year since we were at ESMO in Copenhagen, in what was probably the most exciting meeting of the year in many ways.
With the ASCO abstract deadline being in Jan/Feb, ESMO offers a great opportunity for companies to have another major slot in the calendar to present ground breaking data. In some ways, having positive data at a European meeting can actually amplify positive studies that might otherwise get lost in the noise at ASCO, which is almost becoming too big.
So what’s in store now that the meeting is upon us?
There are some large and small trials with important data on the first two days that bear thinking about and further discussion.
Here’s our take on the first batch of readouts, including some surprises…
Subscribers can log-in to read our latest insights or you can gain access to BSB Premium Content.